MiR203 Lost Suppressor Genes Function in the Process of Barrett’s Esophagus Carcinogenesis Because of High Methylation in Promoter

Liu Tianyu; Long Xiaoqi

doi:doi:10.11648/j.cmr.20190801.14

| Peer-Reviewed

MiR203 Lost Suppressor Genes Function in the Process of Barrett’s Esophagus Carcinogenesis Because of High Methylation in Promoter

Liu Tianyu, Long Xiaoqi

Published in Clinical Medicine Research (Volume 8, Issue 1)

Received: 13 November 2018 Accepted: 11 January 2019 Published: 1 April 2019

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

This study was designed to explore the role of MiR203 promoter methylation in the process of Barrett’s esophagus carcinogenesis. RT-PCR was used to detect the expression levels of miRNA-203 in Barrett’s esophagus, esophageal cancer and normal esophageal mucosa cell lines, before and after the treatment of demethylation. MiR203 promoter methylation levels in these cell lines were measured by Methylation Specific PCR (MSP). Immunohistochemistry was used to test the expression and distribution of K-Ras, a target of miR203, in esophageal cancer, BE and normal esophagus tissues. The following results were found based on the above methods. MiR203 expression levels were reduced obviously in Barrett esophagus and esophageal cancer cells than normal esophageal cells, the difference was statistically significant (P=0.003). After demethylation treatment, miR203 expression levels were significantly increased in Barrett's esophagus and esophageal cancer cells, the differences were statistically significant (P=0.03). MSP results showed that miR203 promoter changed to be low-methylation or non-methylation after demethylation treatment. In conclusion, MiR203 in Barrett's esophagus and esophageal cancer cells reduced expression is related to its Promoter methylation, miR203 promoter methylation throughout the carcinogenesis of Barrett's esophagus, it may become a key molecular biomarker in process of Barrett esophagus cancerous, and may become the prevention and treatment targets of Barrett esophagus carcinogenesis.

Published in	Clinical Medicine Research (Volume 8, Issue 1)
DOI	10.11648/j.cmr.20190801.14
Page(s)	21-26
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2019. Published by Science Publishing Group

Keywords

Barrett's Esophagus, miR203, Methylation, Esophagus Carcinogenesis

References

[1]	Feber A, Xi L, Luketich J D, et a1. MicroRNA expression profiles of esophageal cancer [J]. Thorac Cardiovasc Surg, 2008, 135 (2):255-260.
[2]	Szigeti KA, Galamb O, Kalmár A, et al. Role and alterations of DNA methylation during the aging and cancer [J]. Orv Hetil. 2018, 159 (1):3-15.
[3]	Rahertson KD. DNA methylation and human disease [J]. Nat RevGe net, 2005, 6 (8):597-610.
[4]	Lü L, Liu T, Gao J, et al. Aberrant methylation of microRNA-193b in human Barrett's esophagus and esophageal adenocarcinoma [J]. Mol Med Rep. 2016, 14 (1):283-8.
[5]	Belghazi K1, van Vilsteren FGI1, Weusten BLAM2, et a1. Long-term follow-up results of stepwise radical endoscopic resection for Barrett's esophagus with early neoplasia [J]. Gastrointest Endosc, 2017, 4 (25): 31820-318255.
[6]	Zhang W, Wang DH. Origins of Metaplasia in Barrett's Esophagus: Is this an Esophageal Stem or Progenitor Cell Disease? [J]. Dig Dis Sci. 2018, 63 (8):2005-2012.
[7]	Rajendra S, Sharma P. Barrett Esophagus and Intramucosal Esophageal Adenocarcinoma [J]. Hematol Oncol Clin North Am. 2017 31 (3):409-426.
[8]	Noguchi S, Mori T, Nakagawa T, et a1. DNA methylation contributes toward silencing of antioncogenic microRNA-203 in human and canine melanoma cells [J]. Melanoma Res. 2015, 25 (5):390-398.
[9]	Yang J, Wang S, Wang F, et a1. Downregulation of miR-10b promotes osteoblast differentiation through targeting Bcl6 [J]. Int J Mol Med. 2017, 39 (6):1605-1612.
[10]	Trohatou O, Zagoura D, Orfanos NK, et a1. miR-26a mediates adipogenesis of amniotic fluid mesenchymal stem/stromal cells via PTEN, Cyclin E1, and CDK6 [J]. Stem Cells Dev. 2017, 26 (7):482-494.
[11]	Liu F, Chen N, Xiao R, et a1. MiR-144-3p serves as a tumor suppressor for renal cell carcinoma and inhibits its invasion and metastasis by targeting MAP3K8. Biochem Biophys Res Commun [J]. 2016, 480 (1):87-93.
[12]	Hao Q, Lu X, Liu N, et al. Posttranscriptional deregulation of Src due to aberrant miR34a and miR203 contributes to gastric cancer development [J]. BMB Rep. 2013, 46 (6):316-21.
[13]	Xu D, Wang Q, An Y, et al. MiR-203 regulates the proliferation, apoptosis and cell cycle progression of pancreatic cancer cells by targeting Surviving [J]. Mol Med Rep. 2013; 8 (2):379-84.
[14]	DeCastro AJ, Dunphy KA, Hutchinson J, et al. MiR203 mediates subversion of stem cell properties during mammary epithelial differentiation via repression of ΔNP63αand promotes mesenchymal-to-epithelial transition [J]. Cell Death Dis. 2013 28; 4:e514.
[15]	Wong KY, Liang R, So CC, et al. Epigenetic silencing of MIR203 in multiple myeloma [J]. Br J Haematol. 2011; 154 (5):569-78.
[16]	Qu H, Xu W, Huang Y, Yang S, et al. Circulating miRNAs: Promising Biomarkers of Human Cancer [J]. Asian Pacific journal of cancer prevention: APJCP 2011, 12 (5):1117-25.
[17]	Lee S, Jung JW, Park SB, et al. Histone deacetylase regulates high mobility group A2-targeting microRNAs in human cord blood-derived multipotent stem cell aging [J].. Cell Mol Life Sci. 2011 Jan; 68 (2):325-36.
[18]	Nussinov R, Wang G, Tsai CJ, et al. Calmodulin and PI3K Signaling in KRAS Cancers [J]. Trends Cancer. 2017, 3 (3):214-224.
[19]	Markman B, Javier Ramos F, Capdevila J, et al. EGFR and KRAS in colorectal cancer [J]. Adv Clin Chem, 2010; 51:71-119.
[20]	Sug Hyung Lee, Jong Woo Lee, et al. Young Hwa Soung, et al. BRAF and KRAS mutations in stomach cancer [J]. Oncogene 2003, 22, 6942–6945.
[21]	S. Stremitzer, J. Stift, B. Gruenberger, et al. KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab [J]. British Journal of Surgery, 2012, 99 (11), 1575–1582.
[22]	Nakano H, Yamada Y, Miyazawa T, et al. Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells [J]. Int J Oncol. 2013, 42 (6):1875-82.

Cite This Article

Plain Text BibTeX RIS

APA Style

Liu Tianyu, Long Xiaoqi. (2019). MiR203 Lost Suppressor Genes Function in the Process of Barrett’s Esophagus Carcinogenesis Because of High Methylation in Promoter. Clinical Medicine Research, 8(1), 21-26. https://doi.org/10.11648/j.cmr.20190801.14

Copy | Download

ACS Style

Liu Tianyu; Long Xiaoqi. MiR203 Lost Suppressor Genes Function in the Process of Barrett’s Esophagus Carcinogenesis Because of High Methylation in Promoter. Clin. Med. Res. 2019, 8(1), 21-26. doi: 10.11648/j.cmr.20190801.14

Copy | Download

AMA Style

Liu Tianyu, Long Xiaoqi. MiR203 Lost Suppressor Genes Function in the Process of Barrett’s Esophagus Carcinogenesis Because of High Methylation in Promoter. Clin Med Res. 2019;8(1):21-26. doi: 10.11648/j.cmr.20190801.14

Copy | Download

@article{10.11648/j.cmr.20190801.14,
  author = {Liu Tianyu and Long Xiaoqi},
  title = {MiR203 Lost Suppressor Genes Function in the Process of Barrett’s Esophagus Carcinogenesis Because of High Methylation in Promoter},
  journal = {Clinical Medicine Research},
  volume = {8},
  number = {1},
  pages = {21-26},
  doi = {10.11648/j.cmr.20190801.14},
  url = {https://doi.org/10.11648/j.cmr.20190801.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cmr.20190801.14},
  abstract = {This study was designed to explore the role of MiR203 promoter methylation in the process of Barrett’s esophagus carcinogenesis. RT-PCR was used to detect the expression levels of miRNA-203 in Barrett’s esophagus, esophageal cancer and normal esophageal mucosa cell lines, before and after the treatment of demethylation. MiR203 promoter methylation levels in these cell lines were measured by Methylation Specific PCR (MSP). Immunohistochemistry was used to test the expression and distribution of K-Ras, a target of miR203, in esophageal cancer, BE and normal esophagus tissues. The following results were found based on the above methods. MiR203 expression levels were reduced obviously in Barrett esophagus and esophageal cancer cells than normal esophageal cells, the difference was statistically significant (P=0.003). After demethylation treatment, miR203 expression levels were significantly increased in Barrett's esophagus and esophageal cancer cells, the differences were statistically significant (P=0.03). MSP results showed that miR203 promoter changed to be low-methylation or non-methylation after demethylation treatment. In conclusion, MiR203 in Barrett's esophagus and esophageal cancer cells reduced expression is related to its Promoter methylation, miR203 promoter methylation throughout the carcinogenesis of Barrett's esophagus, it may become a key molecular biomarker in process of Barrett esophagus cancerous, and may become the prevention and treatment targets of Barrett esophagus carcinogenesis.},
 year = {2019}
}

Copy | Download

TY  - JOUR
T1  - MiR203 Lost Suppressor Genes Function in the Process of Barrett’s Esophagus Carcinogenesis Because of High Methylation in Promoter
AU  - Liu Tianyu
AU  - Long Xiaoqi
Y1  - 2019/04/01
PY  - 2019
N1  - https://doi.org/10.11648/j.cmr.20190801.14
DO  - 10.11648/j.cmr.20190801.14
T2  - Clinical Medicine Research
JF  - Clinical Medicine Research
JO  - Clinical Medicine Research
SP  - 21
EP  - 26
PB  - Science Publishing Group
SN  - 2326-9057
UR  - https://doi.org/10.11648/j.cmr.20190801.14
AB  - This study was designed to explore the role of MiR203 promoter methylation in the process of Barrett’s esophagus carcinogenesis. RT-PCR was used to detect the expression levels of miRNA-203 in Barrett’s esophagus, esophageal cancer and normal esophageal mucosa cell lines, before and after the treatment of demethylation. MiR203 promoter methylation levels in these cell lines were measured by Methylation Specific PCR (MSP). Immunohistochemistry was used to test the expression and distribution of K-Ras, a target of miR203, in esophageal cancer, BE and normal esophagus tissues. The following results were found based on the above methods. MiR203 expression levels were reduced obviously in Barrett esophagus and esophageal cancer cells than normal esophageal cells, the difference was statistically significant (P=0.003). After demethylation treatment, miR203 expression levels were significantly increased in Barrett's esophagus and esophageal cancer cells, the differences were statistically significant (P=0.03). MSP results showed that miR203 promoter changed to be low-methylation or non-methylation after demethylation treatment. In conclusion, MiR203 in Barrett's esophagus and esophageal cancer cells reduced expression is related to its Promoter methylation, miR203 promoter methylation throughout the carcinogenesis of Barrett's esophagus, it may become a key molecular biomarker in process of Barrett esophagus cancerous, and may become the prevention and treatment targets of Barrett esophagus carcinogenesis.
VL  - 8
IS  - 1
ER  -

Copy | Download

Author Information

Liu Tianyu

Department of Digestion and Gastroenterology, Suining Central Hospital Affiliated to Chongqing Medical University, Suining, China
Long Xiaoqi

Department of Digestion and Gastroenterology, Suining Central Hospital Affiliated to Chongqing Medical University, Suining, China

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Liu Tianyu, Long Xiaoqi. (2019). MiR203 Lost Suppressor Genes Function in the Process of Barrett’s Esophagus Carcinogenesis Because of High Methylation in Promoter. Clinical Medicine Research, 8(1), 21-26. https://doi.org/10.11648/j.cmr.20190801.14

Copy | Download

ACS Style

Liu Tianyu; Long Xiaoqi. MiR203 Lost Suppressor Genes Function in the Process of Barrett’s Esophagus Carcinogenesis Because of High Methylation in Promoter. Clin. Med. Res. 2019, 8(1), 21-26. doi: 10.11648/j.cmr.20190801.14

Copy | Download

AMA Style

Liu Tianyu, Long Xiaoqi. MiR203 Lost Suppressor Genes Function in the Process of Barrett’s Esophagus Carcinogenesis Because of High Methylation in Promoter. Clin Med Res. 2019;8(1):21-26. doi: 10.11648/j.cmr.20190801.14

Copy | Download

@article{10.11648/j.cmr.20190801.14,
  author = {Liu Tianyu and Long Xiaoqi},
  title = {MiR203 Lost Suppressor Genes Function in the Process of Barrett’s Esophagus Carcinogenesis Because of High Methylation in Promoter},
  journal = {Clinical Medicine Research},
  volume = {8},
  number = {1},
  pages = {21-26},
  doi = {10.11648/j.cmr.20190801.14},
  url = {https://doi.org/10.11648/j.cmr.20190801.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cmr.20190801.14},
  abstract = {This study was designed to explore the role of MiR203 promoter methylation in the process of Barrett’s esophagus carcinogenesis. RT-PCR was used to detect the expression levels of miRNA-203 in Barrett’s esophagus, esophageal cancer and normal esophageal mucosa cell lines, before and after the treatment of demethylation. MiR203 promoter methylation levels in these cell lines were measured by Methylation Specific PCR (MSP). Immunohistochemistry was used to test the expression and distribution of K-Ras, a target of miR203, in esophageal cancer, BE and normal esophagus tissues. The following results were found based on the above methods. MiR203 expression levels were reduced obviously in Barrett esophagus and esophageal cancer cells than normal esophageal cells, the difference was statistically significant (P=0.003). After demethylation treatment, miR203 expression levels were significantly increased in Barrett's esophagus and esophageal cancer cells, the differences were statistically significant (P=0.03). MSP results showed that miR203 promoter changed to be low-methylation or non-methylation after demethylation treatment. In conclusion, MiR203 in Barrett's esophagus and esophageal cancer cells reduced expression is related to its Promoter methylation, miR203 promoter methylation throughout the carcinogenesis of Barrett's esophagus, it may become a key molecular biomarker in process of Barrett esophagus cancerous, and may become the prevention and treatment targets of Barrett esophagus carcinogenesis.},
 year = {2019}
}

Copy | Download

TY  - JOUR
T1  - MiR203 Lost Suppressor Genes Function in the Process of Barrett’s Esophagus Carcinogenesis Because of High Methylation in Promoter
AU  - Liu Tianyu
AU  - Long Xiaoqi
Y1  - 2019/04/01
PY  - 2019
N1  - https://doi.org/10.11648/j.cmr.20190801.14
DO  - 10.11648/j.cmr.20190801.14
T2  - Clinical Medicine Research
JF  - Clinical Medicine Research
JO  - Clinical Medicine Research
SP  - 21
EP  - 26
PB  - Science Publishing Group
SN  - 2326-9057
UR  - https://doi.org/10.11648/j.cmr.20190801.14
AB  - This study was designed to explore the role of MiR203 promoter methylation in the process of Barrett’s esophagus carcinogenesis. RT-PCR was used to detect the expression levels of miRNA-203 in Barrett’s esophagus, esophageal cancer and normal esophageal mucosa cell lines, before and after the treatment of demethylation. MiR203 promoter methylation levels in these cell lines were measured by Methylation Specific PCR (MSP). Immunohistochemistry was used to test the expression and distribution of K-Ras, a target of miR203, in esophageal cancer, BE and normal esophagus tissues. The following results were found based on the above methods. MiR203 expression levels were reduced obviously in Barrett esophagus and esophageal cancer cells than normal esophageal cells, the difference was statistically significant (P=0.003). After demethylation treatment, miR203 expression levels were significantly increased in Barrett's esophagus and esophageal cancer cells, the differences were statistically significant (P=0.03). MSP results showed that miR203 promoter changed to be low-methylation or non-methylation after demethylation treatment. In conclusion, MiR203 in Barrett's esophagus and esophageal cancer cells reduced expression is related to its Promoter methylation, miR203 promoter methylation throughout the carcinogenesis of Barrett's esophagus, it may become a key molecular biomarker in process of Barrett esophagus cancerous, and may become the prevention and treatment targets of Barrett esophagus carcinogenesis.
VL  - 8
IS  - 1
ER  -

Copy | Download